This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Markets, Covid Deaths at New All-Time Highs
by Mark Vickery
The coronavirus posted a new one-day high in both cases -- 241,620 -- and fatalities -- 3,438 -- on Thursday.
Markets Set New Record Closes; FedEx Beats on Q2 (revised)
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
Markets Set New Record Closes; FedEx Beats on Q2
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
Stock Market News for Dec 16, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday buoyed by investors' renewed hopes for a fresh round of coronavirus-aid package by this week end.
Earn 7% Plus Yield With These ETFs
by Sanghamitra Saha
These ETFs offer at least 7% in annual yield.
Industrial Production Beats Expectations in November
by Zacks Equity Research
Industrial Production Beats Expectations in November.
Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout
by Sweta Killa
The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.
Markets Swing Back Up on Vaccine Positivity
by Mark Vickery
Import Prices, Empire State and Industrial Production numbers join new positive data from the FDA on Moderna's (MRNA) vaccine candidate.
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins
by Tirthankar Chakraborty
Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -
Why IPO ETFs are Soaring in 2020
by Neena Mishra
These ETFs provide diversified exposure to hottest IPOs
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
6 Consumer Discretionary ETFs Riding on Holiday Fervor
by Sweta Killa
U.S. consumers grew more confident in the economy in early December on the prospects of a vaccine, which has bolstered the holiday mood.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
Stocks Decline modestly, but Vaccine Optimism Promises a New Rally
by David Borun
A massive rollout of vaccine distribution is the best hope yet for a "return to normal."
ETFs to Win & Lose From the Surge in Oil Price
by Sweta Killa
Oil price has been on a surge in recent months buoyed by solid development on the COVID-19 vaccine front.
Biotech ETF (SBIO) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod
by Kinjel Shah
FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.
5 Energy ETFs Making the Most of the Oil Rally
by Sweta Killa
After registering the best month ever, the energy sector continued its bullish trend on vaccine optimism,
Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine